



**HAL**  
open science

## **Impact of HCV treatment and depressive symptoms on adherence to HAART among coinfecting HIV-HCV patients: results from the ANRS-CO13-HEPAVIH cohort.**

Perrine Roux, Caroline Lions, Julien Cohen, Maria Winnock, Dominique Salmon-Céron, Firouzé Bani-Sadr, Philippe Sogni, Bruno Spire, François Dabis, Maria Patrizia Carrieri

### ► **To cite this version:**

Perrine Roux, Caroline Lions, Julien Cohen, Maria Winnock, Dominique Salmon-Céron, et al.. Impact of HCV treatment and depressive symptoms on adherence to HAART among coinfecting HIV-HCV patients: results from the ANRS-CO13-HEPAVIH cohort.. *Antiviral Therapy*, 2014, 19 (2), pp.171-8. 10.3851/IMP2699 . inserm-00903463

**HAL Id: inserm-00903463**

**<https://inserm.hal.science/inserm-00903463v1>**

Submitted on 12 Nov 2013

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

**Impact of HCV treatment and depressive symptoms on adherence to HAART among  
coinfected HIV-HCV patients: results from the ANRS-CO13-HEPAVIH cohort**

Roux Perrine<sup>1,2,3,\$</sup>, Lions Caroline<sup>1,2,3</sup>, Cohen Julien<sup>1,2,3</sup>, Winnock Maria<sup>4</sup>, Salmon-Céron  
Dominique<sup>5</sup>, Bani-Sadr Firouzé<sup>6</sup>, Sogni Philippe<sup>7,8</sup>, Spire Bruno<sup>1,2,3</sup>, Dabis François<sup>4</sup>, Carrieri  
MPatrizia<sup>1,2,3</sup> for the ANRS CO 13 HEPAVIH Study Group

<sup>1</sup> INSERM UMR912 (SESSTIM), Marseille, France

<sup>2</sup> Université Aix Marseille, IRD, UMR-S912, Marseille, France

<sup>3</sup> ORS PACA, Observatoire Régional de la Santé Provence Alpes Côte d'Azur, Marseille, France

<sup>4</sup> Univ. Bordeaux, ISPED, Bordeaux; INSERM, Centre INSERM U897, 33000 Bordeaux, France

<sup>5</sup> Unité de Maladies Infectieuses, Pôle Médecine - Hôpital COCHIN, Paris, France

<sup>6</sup> Unité des Maladies Infectieuses et Tropicales, Hôpital Robert Debré, Université Champagne Ardenne, Reims, France

<sup>7</sup> Institut Cochin, Université Paris-Descartes, INSERM U567-CNRS (UMR 8104), Paris, France

<sup>8</sup> APHP, Hôpital Cochin, Service d'Hépatologie, Paris

<sup>\$</sup> Corresponding author: INSERM U912 – ORS PACA, 23 rue Stanislas Torrents, 13006 Marseille, France, +33 4 96 10 28 76, + 33 4 96 10 28 99, @: [perrine.roux@inserm.fr](mailto:perrine.roux@inserm.fr)

**Word count:** manuscript = **3165**; abstract = 249.

**Running head:** HCV treatment and adherence to HAART in HIV-HCV coinfecting patients

## **Abstract**

**Background:** The additional burden of HCV infection in HIV-HCV coinfecting individuals may have some consequences on adherence to highly active antiretroviral therapy (HAART). Few studies have explored the pattern of correlates of non-adherence to HAART while simultaneously considering the impact of HCV treatment and depressive symptoms on adherence to HAART. We used longitudinal data to assess factors associated with non-adherence to HAART. **Methods:** The French national prospective cohort ANRS-CO-13-HEPAVIH is a multi-center cohort which recruited 1175 HIV-HCV coinfecting patients in 17 hospital outpatient units delivering HIV and HCV care in France between October 2006 and June 2008. For this analysis, we selected participants on HAART with self-reported data for adherence to HAART (n = 727 patients, 1190 visits). Data were collected using self-administered questionnaires and medical records. A mixed logistic regression model based on an exchangeable correlation matrix was used to identify factors associated with non-adherence to HAART. **Results:** Patients reported non-adherence to HAART in 808 (68%) of the 1190 visits. Four variables remained associated with non-adherence to HAART after multivariate analysis: hazardous alcohol consumption, cocaine use and depressive symptoms, regardless of whether treatment for depression was being received. Finally, patients being treated for HCV infection were less likely to be non-adherent to HAART. **Conclusions:** Besides the problem of polydrug use, two other dimensions deserve special attention when considering adherence to HAART in HIV-HCV coinfecting patients. Access to HCV treatment should be encouraged as well adequate treatment for depression in this population to improve adherence and response to HAART.

**Key words:** adherence, coinfection, depressive symptoms, HIV, HCV, treatment.

## **Introduction**

Adherence to highly active antiretroviral therapy (HAART) is a crucial aspect of medical care in HIV infected patients and has been widely investigated [1, 2]. Many factors have been identified as potential determinants of non-adherence to HAART among monoinfected HIV patients, including medical factors related to care and treatment [3] and non-medical factors such as socio-economic, behavioral and structural determinants e.g. incarceration [4, 5]. The identification of these factors has led to the development of a multidisciplinary approach towards improving adherence to HAART, wherein new interventions to tackle these factors are continuously incorporated. [6]. Part of this approach is to provide improved mental healthcare services for HIV infected persons, the main reason being that psychiatric comorbidities are often associated with chronic diseases [7] in this population [8]. Moreover, mental health and depressive symptoms have a large impact on adherence to HAART [9] and have been the subject of many studies exploring effective clinical strategies to prevent or treat depression [10, 11].

In HIV-HCV coinfecting patients, HCV infection seems to be an independent factor associated with poorer adherence to HAART [12]. In addition, the burden of depression is a challenging concern for HIV clinicians as HIV-HCV individuals are characterized by more severe depression than are their HIV monoinfected counterparts [13]. Moreover, a recent study has shown the first evidence of an association between chronic HCV and recurrent brief episodes of depression, independent of HCV treatment (IFN-alpha) and substance or alcohol abuse [14]. HCV treatment initiation is known to induce depressive symptoms independently of any inherent patient susceptibility to major depression [15]. Besides the fear of HCV treatment inducing depressive symptoms in coinfecting individuals, there is also the worry that it may

have a negative impact of adherence to HAART in this population. This fear was expressed during the most recent IAS conference [16].

The ANRS CO13 HEPAVIH cohort gave us the opportunity to explore the impact of HCV treatment, depressive symptoms and antidepressant treatment on adherence to HAART in a cohort of HIV-HCV coinfecting patients.

## **Methods**

### Study design

The French ANRS-CO13-HEPAVH cohort was designed to study the clinical, immunological, virological, and socio-behavioral course of HIV-HCV coinfecting individuals. This longitudinal study recruited 1175 HIV-HCV coinfecting individuals in 17 outpatient hospital units delivering care to HIV and HCV positive individuals in France between October 2006 and June 2008 and monitored them for 60 months [17].

Individuals enrolled had to be HIV-positive with chronic HCV infection. Those with sustained virological response (undetectable HCV viral load for more than 6 months after treatment for HCV) were not included. Patients who agreed to participate signed a letter of informed consent and were given a self-administered questionnaire at every annual visit (visits were annual) that included items on socio-demographic characteristics, past and current drug and alcohol use, treatment history, HAART adherence and psychosocial factors.

Clinical and biological data, including HIV viral load, CD4 count and liver fibrosis stage, were evaluated using a different questionnaire given to each clinical center's medical staff.

The study was approved by a French institutional review board.

## Study population

Among the 1175 patients included in the cohort, individuals with decompensated cirrhosis, those who had undergone a liver transplantation, those who had hepatocellular carcinoma and those who had been cured of their HCV infection were initially excluded. Of the remaining 1021 patients, only those receiving HAART (n=954) and whose data on adherence to HAART and on depressive symptoms were available for at least one visit (n=727) - accounting for 1190 visits - were included in the analyses.

## Questionnaires

### *Self-administered questionnaires*

The self-administered questionnaires collected psychosocial and behavioral characteristics at enrolment and at each follow-up visit. They consisted of several sections accounting for approximately 100 items focusing on socio-demographic characteristics, history of drug use, addictive behaviors, adherence to HAART, side effects and depressive symptoms. Demographic information and details about educational level, employment and housing were also collected. For history of drug use and current drug and alcohol use, we documented the year of first drug injection. Each patient's history of substance use was assessed using the Addiction Severity Index (ASI) [18], the substances included for assessment being cannabis, cocaine, heroin, crack, ecstasy, buprenorphine, methadone, amphetamines and hallucinogens. Alcohol consumption was measured using the AUDIT-C questionnaire. Hazardous alcohol consumption was defined as a score  $\geq 4$  for men and  $\geq 3$  for women [19].

Data about patients' perceptions of treatment side effects were collected using a section in the questionnaires exploring the occurrence of 39 symptoms over the previous four weeks, and

the discomfort these symptoms had caused. This section was based on the Symptoms Distress Module proposed by Justice et al. [20] which lists symptoms known to occur while on HAART. It was broadened to include questions on lipodystrophy symptoms and symptoms associated with interferon-based therapy.

Patients' depressive symptomatology was assessed using the Center for Epidemiological Studies Depression scale (CES-D) [21]. Patients' feelings and behaviors over the previous week were used to calculate a global depression score ranging from 0 to 60. The cut-off points 17 and 23 for men and women, respectively, were chosen as indicative of depressive symptoms (DS) [22]. This variable was then combined with the information about use of antidepressant treatment(s) (ADT) during the previous 6 months in order that patients could be classified according to the following categories: “*no depressive symptoms and no ADT*” (which was used as the reference group in the analysis), “*no depressive symptoms and ADT*”, “*depressive symptoms and no ADT*” and “*depressive symptoms and ADT*”.

#### *Measurement of adherence to HAART*

In the self-administered questionnaire, a set of seven questions was used to assess adherence to HAART. At each clinical visit, all HAART-treated patients were asked to list, for each antiretroviral drug, the daily number of prescribed pills they had taken during the four days prior to that particular visit. They were also asked if they had “totally” or “partially” taken their prescribed doses of HAART or had “interrupted their treatment” during the same 4-day period. Patients were considered non-adherent if they reported that they had taken <100% of the total dose of antiretroviral drugs prescribed, and/or if they had not totally followed their prescribed regimen during the 4-day period prior to that particular visit. In addition, the visual analogue scale was used to reclassify those patients whose scale score was <100% as non-adherent. In other words, a patient who reported that he/she was adherent in all previous

questions in the adherence section was nonetheless reclassified as non-adherent if he/she reported a score different from 100% in the visual analog scale (from 1 to 6). This approach has been previously validated using protease inhibitor dosage measurement via urine analysis [23].

### *Medical questionnaire*

A medical questionnaire at enrolment collected retrospective data about the patient's history, including clinical and biological data (HIV viral load, CD4 count, and liver fibrosis stage based on Metavir score, and provided either by biopsy, transient elastometry (Fibroscan™) or FibroTest™ results), together with other data on treatment history, including HAART regimen and HCV treatment.

### Statistical analysis

Analyses were performed for the 727 coinfecting patients (accounting for 1190 visits) who were receiving HAART and who had available data on both depressive symptoms and adherence to HAART. Clinical and psychosocial characteristics of patients, including depressive symptoms, access to HCV therapy, self-reported treatment-related side effects, and drug and alcohol use were tested for their association with adherence to HAART.

To identify factors associated with non-adherence to HAART, we used a mixed logistic regression based on an exchangeable correlation matrix. To avoid situations where strong confounding could have hidden important predictors of non-adherence, a liberal p-value of <0.20 in the univariate analyses was chosen to define the variables to be entered into the selection procedure for the multivariate model. A step-by-step backward procedure based on



the log-likelihood ratio test was used to identify the variables, with a p-value of  $<0.05$ , in the multivariate model.

The association between “depressive symptoms and anti-depressant treatment” and two other variables, “the number of perceived symptoms” and “daily cannabis use”, was also tested.

## **Results**

### **Descriptive analysis**

First, no significant difference was found between participants included in the analyses and those who were not, in terms of socio-demographic and clinical characteristics.

The baseline characteristics of the 727 patients included in the analyses are described in **Table 1**.

From a total of 1190 visits, 296 patients (808 visits, 68% of the 1190 visits) reported being non-adherent to HAART, 346 patients (484 visits, 41%) had depressive symptoms and 196 patients (261 visits, 22%) reported having received ADT in the previous 6 months.

Of the 484 visits where patients reported depressive symptoms, 238 patients (312 visits, 64%) were not being treated for their depression, while 136 patients (172 visits, 36%) were receiving ADT. Of the 706 visits where patients had no depressive symptoms, 421 patients (617 visits, 52%) were not being treated and 76 patients (89 visits, 7%) were receiving ADT.

Hazardous alcohol consumption was reported by 286 patients (397 visits, 33%), daily cannabis use by 125 patients (171 visits, 16%), cocaine use by 78 patients (98 visits) and heroin use by 25 patients (32 visits, 3%). The median [IQR] number of self-reported side effects was 9[4-14].

Finally, 223 patients were receiving HCV therapy (354 visits, 30%).

## Factors associated with non-adherence to HAART

### *Univariate analysis*

**Table 2** shows the crude and adjusted ORs of possible correlates of non-adherence to HAART. The variables which were eligible for the final model are indicated in bold. Some socio-demographic characteristics were found to be associated with adherence: Older patients, those who were employed, those living in a couple and those having comfortable housing were all less likely to be non-adherent to HAART. Certain behavioral and psychological outcomes influenced adherence to HAART in the univariate model: depressive symptoms, antidepressant treatment, daily alcohol consumption, daily cannabis use and cocaine use. Experience of progression to AIDS (CDC stage C) was found to be associated with adherence to HAART. Patients who were being treated for their HCV infection were more likely to be adherent to HAART.

Two additional variables - the number of symptoms and daily cannabis use - were found to be correlates of non-adherence to HAART in the univariate analysis but were not included in the final model as they were collinear with “depressive symptoms and antidepressant treatment” which had a stronger association with the outcome. **Tables 3 and 4** show the significant association between the DS/ADT variable and the number of symptoms or daily cannabis use. Even though the number of symptoms was associated with being treated with antidepressants without having any depressive symptoms, the strongest association (a greater than five-fold higher risk of perceiving depressive symptoms) was in patients who had depressive symptoms, whether they were being treated with antidepressants or not. However, daily cannabis use was associated only with those patients who had depressive symptoms while on antidepressant treatment.

### *Multivariate analyses*

The results show that, after multiple adjustments (**Table 2**), patients who reported hazardous alcohol consumption (OR[95%CI]=1.91[1.27-2.87], p=0.002) and cocaine use (OR[95%CI]=2.26[1.15-4.43], p=0.02) were significantly more likely to be non-adherent to HAART. Patients who reported depressive symptoms were also significantly less adherent to HAART, whether they were being treated for depression (OR [95%CI]= 1.83[1.05-3.22], p=0.03) or not (OR[95%CI]= 1.63[1.04-2.54], p=0.03). Finally, patients who were being treated for HCV infection were less likely to be non-adherent to HAART (OR[95%CI]=0.38 [0.17-0.84], p=0.02).

### **Discussion**

The main results of this study suggest that HIV-HCV coinfecting patients with depressive symptoms are at higher risk of non-adherence to HAART - whether they are on antidepressant treatment or not - and that being treated for HCV has a positive impact on adherence to HAART. Not surprisingly, we also found that cocaine use and alcohol consumption continue to be factors associated with non-adherence to HAART.

In other words, the findings from this large cohort show that initiating HIV-HCV coinfecting patients in HCV treatment may facilitate adherence to HAART. Indeed, it was important to adjust the multivariate model for this variable, as patients who were being treated for HCV infection were more likely to be adherent to HAART. Although this paper focuses more on the impact of depression and antidepressant treatment, the latter result deserves attention. It should be confirmed in a more specific study aimed at examining improved access to treatment for HCV in HIV-HCV coinfecting population [24]. It is known that HIV-HCV

coinfected patients face particular barriers to accessing HCV care. They are more often past or current drug users [25], have more chaotic lifestyles and are seen as people with disrupted lives who find it difficult to adhere to treatment [26].

The main result of the present article concerns the impact of depressive symptoms on adherence to HAART. It is known that depression is very prevalent in HCV-infected people, whether receiving treatment for their HCV infection or not [27]. In addition, it has been shown that high rates of depressive symptoms are related to comorbidities such as HCV in such individuals [13]. Given the higher prevalence of depressive symptoms among HIV-HCV coinfecting individuals [28] and the negative impact of these symptoms on adherence to HAART, optimizing clinical management of depression is crucial. As we expected, our results indicate that depressive symptoms are associated with non-adherence to HAART. This confirms the findings of a recent meta-analysis [29]. However, when we considered those who were receiving ADT, patients who had depressive symptoms while being treated had a higher risk of non-adherence to HAART than those who were not being treated with ADT. This important result may be a sign of inadequacy in the provision of care for depression in some HIV-HCV coinfecting patients receiving HAART.

Yun et al. have already demonstrated the positive impact of antidepressant treatment on adherence to HAART in HIV-infected depressed patients [30]. A previous analysis using the baseline data of Hepaviv cohort showed that patients successfully treated for their depression exhibited similar levels of fatigue impact to those with no depressive symptoms and not taking antidepressant treatment [31]. However, the lack of ADT effectiveness, as indicated by persistent depressive symptoms, may be a sign of severe depression or treatment inadequacy. It would therefore seem important to diagnose depression early on and to treat it effectively in order to optimize HIV care. This is especially true with respect to improving adherence to HAART among HIV-HCV coinfecting patients.

In line with other reports [32, 33] the present study suggests that alcohol use interferes with adherence to HAART. The most worrying issue is that alcohol problems are more prevalent in the HCV-infected population [34] than in their non-HCV infected counterparts. Paying greater attention to heavy alcohol drinkers by proposing psychological and/or pharmacological responses would seem to be of great importance. For instance, some studies have shown interesting findings either using baclofen in HCV-infected patients [35] or behavioral counseling in HCV-infected IDU [36].

In this study, cocaine use was also found to be a factor associated with non-adherence to HAART. Although some studies have found mixed results concerning the negative impact of active drug use on adherence to HAART and viral suppression [37], cocaine use has already been shown to impair a positive response to HAART [38]. The only current therapy offered for cocaine abusers, based on the cognitive behavioral model, seems to be insufficient in terms of reducing cocaine use [39]. New pharmacological responses to cocaine abuse and dependence are needed for HIV-HCV coinfecting patients. Furthermore the development of agonist treatments for cocaine dependence would seem to be an interesting avenue of research to pursue for such HIV-HCV coinfecting patients as the efficacy of opioid maintenance treatment in HIV-infected opioid dependent populations has already been proven [40, 41].

Regarding daily cannabis use, our results showed that patients reported daily cannabis use in 16% of visits during follow-up. This behavior was found to be associated with non-adherence to HAART and had a strong association with having depressive symptoms and being treated with ADP. This group (17%) of patients had more severe depressive symptoms. **Indeed, it is known that cannabis dependence may increase psychiatric comorbidities [42, 43]** and depressive symptoms have been found to be higher in cannabis users [44]. Moreover, we also found that the higher the number of self-reported symptoms the higher the non-adherence to HAART. This is in line with previous studies that have demonstrated that reporting perceived

side-effects decreased adherence to HAART [45]. However, many other studies have highlighted the relationship between depression and perceived symptoms such as pain or fatigue [46], suggesting that HCV-related somatic symptoms may be part of a causal pathway leading to depression. That is why treating depression in this population is important in order to improve adherence to HAART but also to alleviate HCV related symptoms.

Some limitations of this study should be acknowledged. First, the reliability of self-reported adherence remains a concern. However, a meta-analysis has already demonstrated the validity of self-reported measures of adherence [47]. To control for social desirability bias, we used a high cut-off score and an algorithm reclassifying patients reporting non-adherence at least once in the adherence questionnaire as non-adherent. Second, the CES-D scale includes several items that measure somatic and physical symptoms of depression. One limitation of using this tool is that physical symptoms are not specific to depression. In depressed patients with HIV infection, certain symptoms such as loss of appetite, sleep disturbances, difficulty in concentration, fatigue, could be confounded with the physical symptoms of the underlying medical condition. However, as we adjusted the statistical model for HIV variables, any confounding effect of HIV symptoms should be limited. Moreover, the use of the CES-D scale to diagnose depression could be criticized because of its lack of clinical accuracy in terms of measuring major depression. Complementing it with other scales could, potentially, improve its screening power [48]. However, the CES-D scale still remains an appropriate tool for detecting depressive symptoms with gender-specific cut-off values [49]. Another limitation of this study is that we did not study adherence to ADT. Had we done so, we could have investigated whether the inefficacy of ADT among patients who reported depressive symptoms was due to poor ADT treatment adherence.

Our results, which focus on depression management, highlight the need to take into account psychiatric comorbidities among HIV-HCV coinfecting persons. The risk of depression induced by HCV therapy is widely recognized [50]. Accordingly, assessment and prompt treatment of depressive symptoms before and after treatment initiation [51] should be recommended. Continuously assessing the effectiveness of such treatment is of paramount importance. While a previous study demonstrated that self-reported fatigue and depression are major components of the different dimensions of the quality of life in HIV-HCV coinfecting patients not receiving anti-HCV treatment [52], our findings underline the importance in identifying psychiatric symptoms to help HIV-HCV coinfecting patients (on HCV treatment or not) to manage multiple therapeutic regimens. Moreover, increasing the range of available therapeutic options, including adequate antidepressant treatment, treatment for alcohol and cocaine dependence as well as other medications to relieve side-effects, should be considered in the early stages of coinfection in order to provide adequate care to the different profiles of this vulnerable population.

### **Acknowledgements**

This study was sponsored and funded by the French National Agency for Research on Aids and Viral Hepatitis (ANRS), with the participation of Abbott France, Glaxo-Smith-Kline, Roche, Schering-Plough and INSERM's 'Programme Cohortes TGIR'.

Carrieri P, Bani-Sadr F, Winnock M, Salmon-Céron D, Sogni P, Dabis F and Spire B were involved in the study concept and design as well as the acquisition of data. Statistical analyses and interpretation of data were performed by Carrieri P, Cohen J, Roux P and Spire B. Roux P was principally involved in the drafting of the manuscript under the supervision of Carrieri P and Spire B. We thank all members of the ANRS CO 13 HEPAVIH study group. We especially thank all physicians and nurses who are involved in the follow-up of the cohort and

all patients who took part in this study. Finally, we thank Jude Sweeney for the English revision and editing of our manuscript.

**Scientific Committee of the ANRS CO13 HEPAVIH Study Group**

D Salmon (principal investigator), F Dabis (principal investigator), M Winnock, MA Loko, P Sogni, Y Benhamou, P Trimoulet, J Izopet, V Paradis, B Spire, P Carrieri, C Katlama, G Pialoux, MA Valantin, P Bonnard, I Poizot-Martin, B Marchou, E Rosenthal, D Garipuy, O Bouchaud, A Gervais, C Lascoux-Combe, C Goujard, K Lacombe, C Duvivier, D Vittecoq, D Neau, P Morlat, F BaniSadr, L Meyer, F Boufassa, S Dominguez, B Autran, AM Roque, C Solas, H Fontaine, L Serfaty, G Chêne, D Costagliola, D Zucman, A Simon, S Dominguez, E Billaud, P Mialhes, J Polo Devoto, S Couffin-Cadiergues (ANRS).

**Clinical Centres (ward / participating physicians):** CHU Cochin (Médecine Interne et Maladies Infectieuses / D Salmon, H Mehawej; Hépatogastro-entérologie / P Sogni; Anatomopathologie / B Terris, Z Makhoul, G Dubost, F Tessier, L Gibault, F Beuvon, E Chambon, T Lazure; Virologie / A Krivine); CHU Pitié-Salpêtrière (Maladies Infectieuses et Tropicales / C Katlama, MA Valantin, H Stitou; Hépatogastro-entérologie / Y Benhamou; Anatomopathologie / F Charlotte; Virologie / S Fourati); CHU Pitié-Salpêtrière (Médecine Interne / A Simon, P Cacoub, S Nafissa; Anatomopathologie / F Charlotte; Virologie / S Fourati), CHU Sainte-Marguerite, Marseille (Service d'Immuno-Hématologie Clinique - CISIH/ I Poizot-Martin, O Zaegel, A Ménard; P Geneau, Virologie / C Tamalet); CHU Tenon (Maladies Infectieuses et Tropicales / G Pialoux, P Bonnard, F Bani-Sadr, L Slama, T Lyavanc; Anatomopathologie / P Callard, F Bendjaballah; Virologie / C Le-Pendevan); CHU Purpan Toulouse (Maladies Infectieuses et Tropicales / B Marchou; Hépatogastro-entérologie / L Alric, K Barange, S Metivier; A Fooladi, Anatomopathologie / J Selves;



Virologie / F Nicot); CHU Archet, Nice (Médecine Interne / E Rosenthal ; Infectiologie / J Durant; Anatomopathologie / J Haudebourg, MC Saint-Paul); CHU Avicenne, Paris (Médecine Interne – Unité VIH / O Bouchaud; Anatomopathologie / M Ziol; Virologie / Y Baazia); Hôpital Joseph-Ducuing, Toulouse (Médecine Interne / M Uzan, A Bicart-See, D Garipuy; MJ Ferro-Collados, Anatomopathologie / J Selves; Virologie / F Nicot); CHU Bichat – Claude-Bernard, Paris (Maladies Infectieuses / P Yéni, A Gervais; Anatomopathologie / H Adle-Biassette); CHU Saint-Louis (Maladies infectieuses / JM Molina, C Lascoux Combe; Anatomopathologie / P Bertheau, J Duclos; Virologie / P Palmer); CHU Saint Antoine (Maladies Infectieuses et Tropicales / PM Girard, K Lacombe, P Campa; Anatomopathologie / D Wendum, P Cervera, J Adam; Virologie / N Harchi); CHU Bicêtre (Médecine Interne / JF Delfraissy, C Goujard, Y Quertainmont; Virologie / C Pallier); CHU Paul-Brousse (Maladies Infectieuses / D Vittecoq); CHU Necker (Maladies Infectieuses et Tropicales / O Lortholary, C Duvivier, M Shoai-Tehrani), ANRS CO 3 Aquitaine cohort (D Neu, P Morlat, L Lacaze-Buzy, S Caldato; Anatomopathologie / P Bioulac-Sage; Virologie / P Trimoulet, S Reigadas), Hôpital FOCH, Suresnes (Médecine Interne / D Zucman, C Majerholc ; Virologie / F Guitard), CHU Antoine Béchère (Médecine Interne / F Boue, J Polo Devoto, I Kansau, V Chambrin, C Pignon, L Berroukeche, R Fior, V Martinez; Virologie / C Deback), CHU Henri Mondor (Immunologie Clinique / Y Lévy, S Dominguez, JD Lelièvre, AS Lascaux, G Melica), CHU Hôtel Dieu, Nantes (Maladies Infectieuses et Tropicales / F Raffi, E Billaud, C Alavena; Virologie / A Rodallec), Hôpital de la Croix Rousse, Lyon ( D Peyramond, C Chidiac, P Mialhes, F Ader, F Biron, A Boibieux, L Cotte, T Ferry, T Perpoint, J Koffi, F Zoulim, F Bailly, P Lack, M Maynard, S Radenne, M Amiri; Virologie / Le-Thi Than-Thuy)

**Data collection, management and statistical analyses:** D Beniken, AS Ritleng, M Azar, P Honoré, S Breau, A Joulie, M Mole, C Bolliot, F Chouraqui, F Touam, F André, N Ouabdesselam, C Partouche, G Alexandre, A Ganon, A Champetier, H Hue, D Brosseau, C Brochier, V Thoirain, M Rannou, D Bornarel, S Gillet, J Delaune, E Pambrun, L Dequae Merchadou, A Frosch, J Cohen, G Maradan, C Taieb, F Marcellin, M Mora, C Protopopescu, P Roux, C Lions, MA Loko, M Winnock.

### **Disclosure statement**

The authors have no conflict of interest to declare.

### **References**

1. **Ortego C, Huedo-Medina TB, Llorca J, et al. Adherence to highly active antiretroviral therapy (HAART): a meta-analysis. *AIDS Behav* 2011; 15(7): 1381-96.**
2. **Mills EJ, Nachega JB, Bangsberg DR, et al. Adherence to HAART: a systematic review of developed and developing nation patient-reported barriers and facilitators. *PLoS Med* 2006; 3(11): e438.**
3. **Lal LS, Grimes RM, Swint JM, Risser J. A retrospective study to determine the impact of medical- and lifestyle-based contraindications to a prescribed HAART regimen on clinical outcomes and adherence. *J Clin Pharm Ther* 2006; 31(5): 429-39.**
4. **Leaver CA, Bargh G, Dunn JR, Hwang SW. The effects of housing status on health-related outcomes in people living with HIV: a systematic review of the literature. *AIDS Behav* 2007; 11(6 Suppl): 85-100.**
5. **Palepu A, Tyndall MW, Chan K, Wood E, Montaner JS, Hogg RS. Initiating highly active antiretroviral therapy and continuity of HIV care: the impact of incarceration and prison release on adherence and HIV treatment outcomes. *Antivir Ther* 2004; 9(5): 713-9.**
6. **Frick P, Tapia K, Grant P, Novotny M, Kerzee J. The effect of a multidisciplinary program on HAART adherence. *AIDS Patient Care STDS* 2006; 20(7): 511-24.**
7. **Wells KB, Golding JM, Burnam MA. Psychiatric disorder in a sample of the general population with and without chronic medical conditions. *Am J Psychiatry* 1988; 145(8): 976-81.**
8. **Orlando M, Burnam MA, Beckman R, et al. Re-estimating the prevalence of psychiatric disorders in a nationally representative sample of persons receiving care for HIV: results from the HIV Cost and Services Utilization Study. *Int J Methods Psychiatr Res* 2002; 11(2): 75-82.**

9. Starace F, Ammassari A, Trotta MP, et al. Depression is a risk factor for suboptimal adherence to highly active antiretroviral therapy. *J Acquir Immune Defic Syndr* 2002; 31 Suppl 3: S136-9.
10. Treisman G, Angelino A. Interrelation between psychiatric disorders and the prevention and treatment of HIV infection. *Clin Infect Dis* 2007; 45 Suppl 4: S313-7.
11. Markowitz JC, Kocsis JH, Fishman B, et al. Treatment of depressive symptoms in human immunodeficiency virus-positive patients. *Arch Gen Psychiatry* 1998; 55(5): 452-7.
12. Braitstein P, Justice A, Bangsberg DR, et al. Hepatitis C coinfection is independently associated with decreased adherence to antiretroviral therapy in a population-based HIV cohort. *Aids* 2006; 20(3): 323-31.
13. Yoon JC, Crane PK, Ciechanowski PS, Harrington RD, Kitahata MM, Crane HM. Somatic symptoms and the association between hepatitis C infection and depression in HIV-infected patients. *AIDS Care* 2011; 23(10): 1208-18.
14. Carta MG, Angst J, Moro MF, et al. Association of chronic hepatitis C with recurrent brief depression. *J Affect Disord* 2012.
15. Schlaak JF, Trippler M, Hoyo-Becerra C, et al. Selective hyper-responsiveness of the interferon system in major depressive disorders and depression induced by interferon therapy. *PLoS One* 2012; 7(6): e38668.
16. G.Dore. Access to HCV treatment for people with HIV/HCV. In: *International AIDS Conference*. Washington DC, 2012.
17. Loko MA, Salmon D, Carrieri P, et al. The French national prospective cohort of patients co-infected with HIV and HCV (ANRS CO13 HEPAVIH): early findings, 2006-2010. *BMC Infect Dis* 2010; 10: 303.
18. McLellan AT, Kushner H, Metzger D, et al. The Fifth Edition of the Addiction Severity Index. *J Subst Abuse Treat* 1992; 9(3): 199-213.
19. Bradley KA, DeBenedetti AF, Volk RJ, Williams EC, Frank D, Kivlahan DR. AUDIT-C as a brief screen for alcohol misuse in primary care. *Alcohol Clin Exp Res* 2007; 31(7): 1208-17.
20. Justice AC, Holmes W, Gifford AL, et al. Development and validation of a self-completed HIV symptom index. *J Clin Epidemiol* 2001; 54 Suppl 1: S77-90.
21. Furher R, Rouillon F. La version française de l'échelle CES-D. Description and translation of the auto-evaluation [in French]. *Psychiatrie et Psychobiologie* 1989; 4: 163-6.
22. Radloff L. The CES-D scale: a self-report depression scale for research in the general population. *Appl Psychol Measure* 1977; 3: 385-491.
23. Duran S, Solas C, Spire B, et al. 'Do HIV-infected injecting drug users over-report adherence to highly active antiretroviral therapy?' A comparison between patients' self-reports and serum protease inhibitor concentrations in the French Manif 2000 cohort study. *Aids* 2001; 15(8): 1075-7.
24. Soriano V, Sherman KE, Rockstroh J, et al. Challenges and opportunities for hepatitis C drug development in HIV-hepatitis C virus-co-infected patients. *AIDS* 2011; 25(18): 2197-208.
25. Strader DB. Coinfection with HIV and hepatitis C virus in injection drug users and minority populations. *Clin Infect Dis* 2005; 41 Suppl 1: S7-13.
26. Stein MD, Herman DS, Solomon DA, et al. Adherence to treatment of depression in active injection drug users: the minerva study. *J Subst Abuse Treat* 2004; 26(2): 87-93.

27. Schaefer M, Capuron L, Friebe A, et al. Hepatitis C infection, antiviral treatment and mental health: A European expert consensus statement. *J Hepatol* 2012.
28. Libman H, Saitz R, Nunes D, et al. Hepatitis C infection is associated with depressive symptoms in HIV-infected adults with alcohol problems. *Am J Gastroenterol* 2006; 101(8): 1804-10.
29. Gonzalez JS, Batchelder AW, Psaros C, Safren SA. Depression and HIV/AIDS treatment nonadherence: a review and meta-analysis. *J Acquir Immune Defic Syndr* 2011; 58(2): 181-7.
30. Yun LW, Maravi M, Kobayashi JS, Barton PL, Davidson AJ. Antidepressant treatment improves adherence to antiretroviral therapy among depressed HIV-infected patients. *J Acquir Immune Defic Syndr* 2005; 38(4): 432-8.
31. Michel L, Villes V, Dabis F, et al. Role of treatment for depressive symptoms in relieving the impact of fatigue in HIV-HCV co-infected patients: ANRS Co13 Hepaviv, France, 2006-2008. *J Viral Hepat* 2010.
32. Kresina TF, Flexner CW, Sinclair J, et al. Alcohol use and HIV pharmacotherapy. *AIDS Res Hum Retroviruses* 2002; 18(11): 757-70.
33. Samet JH, Horton NJ, Meli S, Freedberg KA, Palepu A. Alcohol consumption and antiretroviral adherence among HIV-infected persons with alcohol problems. *Alcohol Clin Exp Res* 2004; 28(4): 572-7.
34. Campbell JV, Hagan H, Latka MH, et al. High prevalence of alcohol use among hepatitis C virus antibody positive injection drug users in three US cities. *Drug Alcohol Depend* 2006; 81(3): 259-65.
35. Leggio L, Ferrulli A, Zambon A, et al. Baclofen promotes alcohol abstinence in alcohol dependent cirrhotic patients with hepatitis C virus (HCV) infection. *Addict Behav* 2012; 37(4): 561-4.
36. Drumright LN, Hagan H, Thomas DL, et al. Predictors and effects of alcohol use on liver function among young HCV-infected injection drug users in a behavioral intervention. *J Hepatol* 2011; 55(1): 45-52.
37. Kerr T, Marshall BD, Milloy MJ, et al. Patterns of heroin and cocaine injection and plasma HIV-1 RNA suppression among a long-term cohort of injection drug users. *Drug Alcohol Depend* 2012; 124(1-2): 108-12.
38. Sharpe TT, Lee LM, Nakashima AK, Elam-Evans LD, Fleming PL. Crack cocaine use and adherence to antiretroviral treatment among HIV-infected black women. *J Community Health* 2004; 29(2): 117-27.
39. Dutra L, Stathopoulou G, Basden SL, Leyro TM, Powers MB, Otto MW. A meta-analytic review of psychosocial interventions for substance use disorders. *Am J Psychiatry* 2008; 165(2): 179-87.
40. Grabowski J, Rhoades H, Stotts A, et al. Agonist-like or antagonist-like treatment for cocaine dependence with methadone for heroin dependence: two double-blind randomized clinical trials. *Neuropsychopharmacology* 2004; 29(5): 969-81.
41. Rush CR, Stoops WW. Agonist replacement therapy for cocaine dependence: a translational review. *Future Med Chem* 2012; 4(2): 245-65.
42. Dakwar E, Nunes EV, Bisaga A, et al. A comparison of independent depression and substance-induced depression in cannabis-, cocaine-, and opioid-dependent treatment seekers. *Am J Addict* 2011; 20(5): 441-6.
43. Looby A, Earleywine M. Negative consequences associated with dependence in daily cannabis users. *Subst Abuse Treat Prev Policy* 2007; 2: 3.
44. Bovasso GB. Cannabis abuse as a risk factor for depressive symptoms. *Am J Psychiatry* 2001; 158(12): 2033-7.

45. **Carrieri MP, Leport C, Protopopescu C, et al. Factors associated with nonadherence to highly active antiretroviral therapy: a 5-year follow-up analysis with correction for the bias induced by missing data in the treatment maintenance phase. *J Acquir Immune Defic Syndr* 2006; 41(4): 477-85.**
46. **Sullivan PS, Dworkin MS. Prevalence and correlates of fatigue among persons with HIV infection. *J Pain Symptom Manage* 2003; 25(4): 329-33.**
47. **Nieuwkerk PT, Oort FJ. Self-reported adherence to antiretroviral therapy for HIV-1 infection and virologic treatment response: a meta-analysis. *J Acquir Immune Defic Syndr* 2005; 38(4): 445-8.**
48. **Golub ET, Latka M, Hagan H, et al. Screening for depressive symptoms among HCV-infected injection drug users: examination of the utility of the CES-D and the Beck Depression Inventory. *J Urban Health* 2004; 81(2): 278-90.**
49. **Fuhrer R, Rouillon F, Lellouch J. Diagnostic reliability among French psychiatrists using DSM-III criteria. *Acta Psychiatr Scand* 1986; 73(1): 12-6.**
50. **Reichenberg A, Gorman JM, Dieterich DT. Interferon-induced depression and cognitive impairment in hepatitis C virus patients: a 72 week prospective study. *Aids* 2005; 19 Suppl 3: S174-8.**
51. **Laguno M, Blanch J, Murillas J, et al. Depressive symptoms after initiation of interferon therapy in human immunodeficiency virus-infected patients with chronic hepatitis C. *Antivir Ther* 2004; 9(6): 905-9.**
52. **Marcellin F, Preau M, Ravaux I, Dellamonica P, Spire B, Carrieri MP. Self-reported fatigue and depressive symptoms as main indicators of the quality of life (QOL) of patients living with HIV and Hepatitis C: implications for clinical management and future research. *HIV Clin Trials* 2007; 8(5): 320-7.**

**Table 1.** Baseline characteristics of the sample used for the analyses, n=727.

	Number of patients (%)	Median [IQR]
<b>Female gender</b>	224 (31)	
<b>Age<sup>a</sup></b>		44[41-48]
<b>Being employed</b>	371 (51)	
<b>Having children</b>	236 (33)	
<b>High school certificate</b>	195 (27)	
<b>Living in a couple</b>	345 (47)	
<b>Comfortable housing</b>	603 (83)	
<b>Owner or tenant of her/his home</b>	579 (80)	
<b>HIV transmission group</b>		
- injecting drug use (IDU)	472 (65)	
- men who have sex with men (MSM)	85 (12)	
- heterosexual	100 (14)	
- “don’t know” or “other”	70 (9)	
<b>Daily cannabis use<sup>b</sup></b>	105 (14)	
<b>Hazardous alcohol consumption<sup>c</sup></b>	251 (35)	
<b>Cocaine use<sup>b</sup></b>	61 (8)	
<b>Heroin use<sup>b</sup></b>	19 (3)	
<b>CDC stage C</b>	221 (30)	
<b>CD4 cell count</b>		449 [302-648]
<b>HIV undetectable viral load (&lt;50 copies/ml)</b>	533 (73)	
<b>Severe fibrosis</b>	219 (30)	

<sup>a</sup> Per 10-year increase

<sup>b</sup> during the previous month

<sup>c</sup> AUDIT-C score  $\geq 4$  for men and  $\geq 3$  for women

**Table 2.** Factors associated with non-adherence to HAART: mixed logistic model, univariate and multivariate analysis (1190 visits, 727 patients)

	Number of visits (%) or median [IQR]	Number of patients	Univariate analysis		Multivariate analysis	
			OR [95%CI]	p-value	aOR [95%CI]	p-value
Female gender	363 (31)	224	0.94 [0.58-1.51]	0.80		
<b>Age<sup>a</sup></b>	<b>45 [42-48]</b>		<b>0.76 [0.54-1.09]</b>	<b>0.14</b>		
<b>Being employed</b>	<b>581 (50)</b>	<b>387</b>	<b>0.71 [0.47-1.08]</b>	<b>0.11</b>		
Having children	366 (31)	247	0.99 [0.62-1.57]	0.96		
High school certificate	321 (31)	185	0.73 [0.43-1.23]	0.24		
<b>Living in a couple</b>	<b>567 (48)</b>	<b>368</b>	<b>0.69 [0.45-1.06]</b>	<b>0.09</b>		
<b>Comfortable housing</b>	<b>994 (84)</b>	<b>630</b>	<b>0.47 [0.25-0.80]</b>	<b>0.005</b>		
Owner or tenant of her/his home	966 (82)	604	0.89 [0.52-1.50]	0.65		
<b>Depressive symptoms (DS)<sup>b</sup> and antidepressant treatment (ADT)</b>						
- no DS/no ADT (ref)	617 (52)	421	1		1	
- no DS/ADT	89 (7)	76	1.30 [0.62-2.70]	0.49	1.31 [0.64-2.71]	0.46
- DS/no ADT	<b>312 (26)</b>	<b>238</b>	<b>1.63 [1.04-2.57]</b>	<b>0.03</b>	<b>1.63 [1.04-2.54]</b>	<b>0.03</b>
- DS/ADT	<b>172 (14)</b>	<b>136</b>	<b>2.02 [1.15-3.58]</b>	<b>0.02</b>	<b>1.83 [1.05-3.22]</b>	<b>0.03</b>
<b>Hazardous alcohol consumption<sup>c</sup></b>						
	<b>397 (33)</b>	<b>286</b>	<b>2.26 [1.49-3.42]</b>	<b>&lt;10<sup>-3</sup></b>	<b>1.91 [1.27-2.87]</b>	<b>0.002</b>
<b>Heroin use<sup>d</sup></b>	<b>32 (3)</b>	<b>25</b>	<b>3.79 [1.19-12.05]</b>	<b>0.02</b>		
<b>Cocaine use<sup>d</sup></b>	<b>98 (8)</b>	<b>78</b>	<b>2.85 [1.43-5.67]</b>	<b>0.003</b>	<b>2.26 [1.15-4.43]</b>	<b>0.02</b>
Number of years since HAART initiation <sup>e</sup>						
	3 [1-5]		0.87 [0.59-1.27]	0.46		
<b>CDC stage C</b>	<b>354 (30)</b>	<b>223</b>	<b>0.68 [0.42-1.09]</b>	<b>0.11</b>		
<b>HCV treated</b>	<b>88 (7)</b>		<b>0.33 [0.15-0.75]</b>	<b>0.008</b>	<b>0.38 [0.17-0.84]</b>	<b>0.02</b>
Number of HAART pills per day						
	4 [3-6]		1.01 [0.92-1.09]	0.90		
<b>Number of symptoms<sup>*</sup></b>	<b>9 [4-14]</b>		<b>1.05 [1.02-1.08]</b>	<b>0.002</b>	-	-
<b>Daily cannabis use<sup>*</sup></b>	<b>171 (16)</b>	<b>125</b>	<b>2.21 [1.21-4.06]</b>	<b>0.01</b>	-	-

<sup>a</sup> Per 10-year increase

<sup>b</sup> CES-D score >17 for men and >23 for women

<sup>c</sup> AUDIT-C score ≥4 for men and ≥3 for women

<sup>d</sup> during the previous month

<sup>e</sup> Per 5-year increase

\* not included in the multivariate model

**Table 3.** Association between depressive symptoms variable and number of symptoms: mixed linear model.

	Coeff [95%CI]	p-value
Depressive symptoms <sup>a</sup> and antidepressant treatment		
- no DS/no ADT (ref)	1	
- <b>no DS/ADT</b>	<b>1.93 [0.66-3.21]</b>	<b>0.003</b>
- <b>DS/no ADT</b>	<b>5.45 [4.66-6.25]</b>	<b>&lt;10<sup>-3</sup></b>
- <b>DS/ADT</b>	<b>5.68 [4.66-6.70]</b>	<b>&lt;10<sup>-3</sup></b>

Y=number of perceived symptoms

<sup>a</sup> CES-D score >17 for men and >23 for women

**Table 4.** Association between “depressive symptoms and antidepressant treatment” variable and daily cannabis use: mixed logistic model

	OR [95% CI]	p-value
Depressive symptoms <sup>a</sup> and antidepressant treatment		
- no DS/no ADT (ref)	1	
- no DS/ADT	1.41 [0.44-4.53]	0.57
- DS/no ADT	0.96 [0.45-2.08]	0.93
- <b>DS/ADT</b>	<b>2.65 [1.05-6.70]</b>	<b>0.04</b>

Y=daily cannabis use

<sup>a</sup> CES-D score >17 for men and >23 for women